PH94B
- Generic Name
- PH94B
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- DTW1NJ7IJH
- Background
PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
- Indication
Intended for the acute treatment of social phobia.
- Associated Conditions
- -
- Associated Therapies
- -
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 483
- Registration Number
- NCT05030350
- Locations
- 🇺🇸
VistaGen Investigational Site, Bellevue, Washington, United States
PH94B in the Treatment of Adjustment Disorder With Anxiety
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04404192
- Locations
- 🇺🇸
VistaGen Clinical Site, New York, New York, United States
Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Pherin Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02622958
- Locations
- 🇺🇸
The Medical Research Network, LLC, New York City, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath